Developing the VUMC MICRO facility to advance innovative BSL3 research

开发 VUMC MICRO 设施以推进创新 BSL3 研究

• 批准号: 10596928
• 负责人: Eric P Skaar
• 金额: $ 797.5万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-16 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10596928
• 关键词: Academic Medical Centers; Air; Basic Science; Biomedical Research; COVID-19; Centers for Disease Control and Prevention (U.S.); Communicable Diseases; Ensure; Equipment; Filtration; Goals; Health; Heart; Human; Immunology; Individual; Infection; Inflammation; Infrastructure; Institutes; Institution; Investments; Laboratories; Leadership; Mechanics; Modernization; Pathogenesis; Plumbing; Prevention Guidelines; Procedures; Public Health; Research; Research Personnel; Resources; Silver; Southeastern United States; System; Tennessee; United States National Institutes of Health; Universities; Vaccine Design; Virulent; Work; biosafety level 3 facility; clinical care; design; exhaust; experience; flexibility; innovation; medical schools; microbial; operation; pathogen; research facility; response; square foot; therapeutic development

PROJECT ABSTRACT In response to the global increase and spread of infectious disease and its impact on human health, Vanderbilt University Medical Center (VUMC) has established a trans-institutional strategic framework for infection and immunology research, including significant investments in research focused on highly virulent pathogens. Vanderbilt investigators are rapidly advancing discovery in the fields of microbial pathogenesis, therapeutic development, and vaccine design including critical research combatting COVID-19. Vanderbilt’s growing leadership in microbial pathogenesis makes research at biosafety level 3 (BSL3) critical to enabling breakthroughs. However, Vanderbilt’s two small BSL3 laboratories serve individual investigators and operate at capacity. Most Vanderbilt researchers therefore have no access to BSL3 facilities. The proposed Microbial Infectious Disease Core ResOurce (MICRO) will be a modern, comprehensive BSL3 shared research facility that significantly expands capacity for BSL3 research at Vanderbilt. Regional partnerships with institutions such as the University of Tennessee and Meharry Medical College will advance BSL3 work across the southeastern United States to maximize the MICRO’s benefit and impact. Key project goals will be accomplished through the renovation of 3,587 net square feet (NSF) of space in the heart of Vanderbilt’s biomedical research zone. The MICRO will be flexibly configured to meet stringent isolation requirements for BSL3 and Select Agent pathogens and can be rapidly modified as research and public health needs evolve. The MICRO will contain three BSL3 suites with a total of seven procedure rooms and will be served by new and/or rerouted mechanical and plumbing systems that completely isolate the BSL3 space. A 1,038 NSF BSL3-dedicated space will be constructed to enclose new mechanical equipment, including dedicated air handling units and an exhaust filtration system. The project will be designed to meet LEED Silver standards as well as National Institutes of Health and Centers for Disease Control and Prevention guidelines. The MICRO will be developed and managed by an experienced project manager and BSL3 facility manager working with the Vanderbilt Institute of Infection, Immunology and Inflammation, Office of Research, and Scientific Advisory Board to ensure effective planning, operation, and shared access to the new facility. Overall, the requested renovations will enable substantial improvements in infrastructure, capacity, and capabilities for BSL3 experimentation. This facility will enhance infection and immunology research that will lead to scientific breakthroughs in these fields at the nexus of basic research, clinical care, and public health.

项目摘要 为了应对全球传染病的增加和传播及其对人类健康的影响，范德比尔特大学医学中心（VUMC）建立了一个跨机构的感染和免疫学研究战略框架，包括对高毒力病原体研究的重大投资。范德比尔特的研究人员正在微生物发病机制、治疗开发和疫苗设计领域迅速推进发现，包括对抗COVID-19的关键研究。范德比尔特在微生物发病机制方面的领导地位日益增强，这使得生物安全3级（BSL 3）的研究对于实现突破至关重要。然而，范德比尔特的两个小型BSL 3实验室为个人研究人员服务，并在能力。因此，大多数范德比尔特的研究人员无法使用BSL 3的设施。拟议的微生物传染病核心资源（MICRO）将是一个现代化的，全面的BSL 3共享研究设施，显着扩大了范德比尔特的BSL 3研究能力。与田纳西大学和梅哈里医学院等机构的区域合作伙伴关系将推动美国东南部的BSL 3工作，以最大限度地发挥MICRO的效益和影响。主要项目目标将通过改造范德比尔特生物医学研究区中心的3,587净平方英尺（NSF）空间来实现。MICRO将灵活配置，以满足BSL 3和Select Agent病原体的严格隔离要求，并可根据研究和公共卫生需求的发展进行快速修改。MICRO将包含三个BSL 3套房，共有七个手术室，并将由新的和/或重新布线的机械和管道系统提供服务，完全隔离BSL 3空间。一个1,038 NSF BSL 3专用空间将被建造，以封闭新的机械设备，包括专用的空气处理装置和排气过滤系统。该项目的设计将符合LEED银级标准以及美国国立卫生研究院和疾病控制和预防中心的指导方针。MICRO将由经验丰富的项目经理和BSL 3设施经理与范德比尔特感染、免疫学和炎症研究所、研究办公室和科学咨询委员会合作开发和管理，以确保有效规划、运营和共享新设施。总的来说，要求的改造将使基础设施、容量和BSL 3实验能力得到实质性改善。该设施将加强感染和免疫学研究，从而在基础研究，临床护理和公共卫生的关系中实现这些领域的科学突破。